Latest News and Press Releases

Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2019 VD kommenterar Den 4 juli 2019 kunde vi meddela att den första patienten i IBTs kliniska fas III-studie hade...

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019 Message from the CEO On July 4 we were able to announce that the first patient had been recruited...

Infant Bacterial Therapeutics har rekryterat den första patienten i den pivotala kliniska Fas III-studie, The Connection Study. Utvecklingsprogrammet för IBP-9414, i vilken The Connection Study är den...

IBT has recruited the first patient in the Phase III pivotal clinical study, The Connection Study. The development program for IBP-9414, of which The Connection Study is the final planned clinical...

IBT har under en längre tid rådgjort med den amerikanska läkemedelsmyndigheten FDA (US Food and Drug Administration) angående hur företagets planerade fas III studie skall utformas. FDA har nu i...

IBT has for an extended time consulted with the US Food and Drug Administration (FDA) on how the company's planned Phase III study should be designed. The FDA has now informed IBT in writing that IBT...

På årsstämman i Infant Bacterial Therapeutics AB (publ) den 6 maj 2019 beslöts bland annat följande: fastställande av årsredovisningen beviljad ansvarsfrihet för styrelseledamöter och...

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 6, 2019, among other things, the following was resolved: determination of the annual reportdischarge granted to...

VD kommenterar Som vi tidigare informerat om har IBT haft ett möte med amerikanska Food and Drug Administration (FDA) den 20 november 2018 för att diskutera IBTs kliniska utvecklingsprogram....

Message from the CEO As previously communicated, IBT had a meeting with the Food and Drug Administration (FDA) on November 20, 2018, to discuss IBT’s clinical development program. The development...